RENBP and neoplasm: Together with the results shown in Figure S4, these data collectively indicate that protection from HBV-Ag expressing tumors requires HBV Ag expression in both the vaccine and in the tumor target, and that the lack of complete tumor protection is likely explained in large part by outgrowth of EL4 cells lacking HBV antigen expression.